Global  

Celebrating 10 Years of Trusted News Discovery
One News Page
> >

QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer

Business Wire Friday, 24 May 2019
GERMANTOWN, Md. & HILDEN, Germany--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the immediate launch of its therascreen® PIK3CA RGQ PCR Kit (therascreen PIK3CA Kit) after it received U.S. regulatory approval as a companion diagnostic to aid in identifying breast cancer patients eligible for treatment with PIQRAY (alpelisib), a newly approved therapy developed and marketed by Novartis. The therascreen PIK3CA Kit is the first companion diagnostic assay to ob
0
shares
ShareTweetSavePostSend
 

You Might Like


Recent related news from verified sources

QIAGEN to deliver genomic insights for Japan’s new molecular oncology clinical research and precision medicine initiative

HILDEN, Germany & TOKYO--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QIAGEN Clinical Insight (QCI) offering was...
Business Wire

Sharda Hospital Launches Project Arogya to Spread Awareness about Breast Cancer

Sharda Hospital Launches Project Arogya to Spread Awareness about Breast Cancer
*Sharda Hospital*, a state-of-the-art super-speciality hospital, is a premium model of healthcare extending medical services at par with global...
NewsVoir

Nine out of 10 breast cancer patients foot medical bill

A new study shows that nine out of every 10 breast cancer patients in Nigeria and Ghana have to pay for their breast cancer diagnostic tests and treatment...
Myjoyonline Also reported by •Newsday

Hemispherx Biopharma issues updates for ongoing immunotherapy trials of its drug Ampligen

Hemispherx Biopharma Inc (NYSEAMERICAN:HEB) updated shareholders Monday on the progress of five ongoing immuno-oncology clinical trials for its drug Ampligen....
Proactive Investors

Avalon GloboCare CEO David Jin to unveil exosome commercialization plan at China confab

Avalon GloboCare (NASDAQ:AVCO) announced Thursday that CEO David Jin will unveil the launch of the company’s new commercialization plan for its exosome...
Proactive Investors

Rhythm Biosciences welcomes new ColoSTAT trial member in Monash Health

Rhythm Biosciences Limited (ASX:RHY) has welcomed new trial member Monash Health in joining its prospective clinical trial of ColoSTAT – a global lifesaving...
Proactive Investors

Avalon GloboCare expects to be added to Russell 3000 Index

Avalon GloboCare Corp (NASDAQ:AVCO), a developer of cell-based technologies and therapeutics, announced Tuesday that it expects to be added to the Russell 3000...
Proactive Investors


Other recent news in Press Releases

Triumvira Immunologics Announces Clearance of IND and CTA by U.S. FDA and HEALTH Canada for Its First TAC T-cell Therapeutic Product Candidate, TAC01-CD19PwC and Xero Extend Global Collaboration to Help Small BUSINESS Succeed
Global SOFTWARE Leaders Xero and Stripe Join Forces to Bring Seamless Payments to Millions of Small BusinessesBlonder Tongue Labs Brings In-Room WiFi to their Line of Hospitality Cable Modem PRODUCTS
Environmentally friendly: One News Page is hosted on servers powered solely by renewable energy
© 2019 One News Page Ltd. All Rights Reserved.
About us  |  Contact us  |  Disclaimer  |  Press Room  |  Terms & Conditions  |  Content Accreditation
 RSS  |  News for my Website  |  Free news search widget  |  In the News  |  DMCA / Content Removal  |  Privacy & Data Protection Policy
How are we doing? FeedbackSend us your feedback  |   LIKE us on Facebook   FOLLOW us on Twitter  •  FOLLOW us on Pinterest
One News® is a registered trademark of One News Page Ltd.